PTHrP promotes subchondral bone formation in TMJ-OA.
10.1038/s41368-022-00189-x
- Author:
Jun ZHANG
1
;
Caixia PI
1
;
Chen CUI
1
;
Yang ZHOU
1
;
Bo LIU
2
;
Juan LIU
2
;
Xin XU
1
;
Xuedong ZHOU
1
;
Liwei ZHENG
3
Author Information
1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu, China.
2. Yunnan Key Laboratory of Stomatology, Kunming, China.
3. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu, China. liwei.zheng@scu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
Osteoclasts;
Osteogenesis;
Parathyroid Hormone-Related Protein/pharmacology*;
Temporomandibular Joint;
Transforming Growth Factor beta/pharmacology*
- From:
International Journal of Oral Science
2022;14(1):37-37
- CountryChina
- Language:English
-
Abstract:
PTH-related peptide (PTHrP) improves the bone marrow micro-environment to activate the bone-remodelling, but the coordinated regulation of PTHrP and transforming growth factor-β (TGFβ) signalling in TMJ-OA remains incompletely understood. We used disordered occlusion to establish model animals that recapitulate the ordinary clinical aetiology of TMJ-OA. Immunohistochemical and histological analyses revealed condylar fibrocartilage degeneration in model animals following disordered occlusion. TMJ-OA model animals administered intermittent PTHrP (iPTH) exhibited significantly decreased condylar cartilage degeneration. Micro-CT, histomorphometry, and Western Blot analyses disclosed that iPTH promoted subchondral bone formation in the TMJ-OA model animals. In addition, iPTH increased the number of osterix (OSX)-positive cells and osteocalcin (OCN)-positive cells in the subchondral bone marrow cavity. However, the number of osteoclasts was also increased by iPTH, indicating that subchondral bone volume increase was mainly due to the iPTH-mediated increase in the bone-formation ability of condylar subchondral bone. In vitro, PTHrP treatment increased condylar subchondral bone marrow-derived mesenchymal stem cell (SMSC) osteoblastic differentiation potential and upregulated the gene and protein expression of key regulators of osteogenesis. Furthermore, we found that PTHrP-PTH1R signalling inhibits TGFβ signalling during osteoblastic differentiation. Collectively, these data suggested that iPTH improves OA lesions by enhancing osteoblastic differentiation in subchondral bone and suppressing aberrant active TGFβ signalling. These findings indicated that PTHrP, which targets the TGFβ signalling pathway, may be an effective biological reagent to prevent and treat TMJ-OA in the clinic.
